Back to News
Market Impact: 0.2
Orthocell Achieves Strongest Month of U.S. Remplir™ Sales Since Launch
Source: PR Newswire
Healthcare & BiotechCompany Fundamentals
Orthocell reported sales of 92 Remplir™ nerve-wrap units in October 2026. The company describes the FDA-cleared device as emerging as a category leader in key international markets; the article provides no comparison period or further sales figures.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
More News
- Marvell to buy Lumentum in $115 billion deal in AI data-center bet
- Palantir reports booming U.S. commercial revenue growth, topping government for first time
- Anthropic releases amended IPO prospectus with third-quarter financials
- Coinbase has been battered over the past month. Morgan Stanley says steer clear
- The AI boom is facing another supply crunch. This time it’s the amount of capital available to feed Silicon Valley’s endless need for cash
- Anthropic to Spend $895 Billion in the Years Ahead